Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Sight Sciences announced the publication of clinical data demonstrating the safety and effectiveness of the OMNI Surgical System in treating pseudophakic glaucoma patients. The study, published in International Ophthalmology, highlights the potential of OMNI as a minimally invasive, implant-free solution for patients whose intraocular pressure (IOP) is no longer controlled by existing treatments. Follow-ups of 3 to 42 months revealed that most participants regained IOP control, emphasizing OMNI's role in managing glaucoma throughout its progression.
Sight Sciences, Inc. (Nasdaq: SGHT) will announce its third-quarter financial results on November 10, 2022, after the market close. The management team will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The event will be accessible through a live and archived webcast on the company's website. Sight Sciences focuses on innovative eyecare technology, including the OMNI® Surgical System and the TearCare® System, aimed at addressing prevalent eye diseases and improving patient outcomes.
On September 29, 2022, Sight Sciences (Nasdaq: SGHT) announced the publication of clinical trial data from the OLYMPIA trial in Clinical Ophthalmology. Results indicated that the TearCare System outperformed LipiFlow in improving symptoms for advanced dry eye patients due to meibomian gland dysfunction. The study involved 235 participants and showed statistically significant symptom relief across multiple endpoints, with TearCare achieving a 31% reduction in OSDI scores compared to LipiFlow's 21%. The findings reinforce TearCare's effectiveness as a treatment option.
Sight Sciences announced a first-time preview of the Ergo-Series of the OMNI Surgical System and the new SION Surgical Instrument at the AAO convention in Chicago, IL. Twelve ophthalmic physicians will share their experiences with the OMNI as a standalone treatment for minimally invasive glaucoma surgery (MIGS). These demonstrations highlight the effectiveness of OMNI in lowering intraocular pressure (IOP) while reducing patient medication needs. The event takes place at booth #4843 during the convention.
Sight Sciences announced the OMNI Surgical System will be showcased in seven clinical presentations at the 2022 ESCRS meeting in Milan from September 16-20. This system offers an innovative, implant-free approach to treating glaucoma, addressing key resistance points in the aqueous outflow system. The company highlights the growing adoption of OMNI in cataract procedures. Attendees will engage with leading glaucoma specialists at the booth, and the presentations will include long-term evaluations of OMNI's effectiveness in treating open-angle glaucoma.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced the completion of enrollment in the SAHARA Trial, evaluating the effectiveness of the TearCare® device versus Restasis® eyedrops for chronic dry eye disease. This 310-patient randomized controlled trial aims to assess the superiority of the TearCare procedure in alleviating symptoms and improving eye surface conditions. Six-month efficacy results are expected by Summer 2023, with significant implications for treatment practices in dry eye disease anticipated from the outcome. The trial emphasizes a comprehensive approach to eye care.
Sight Sciences, an eyecare technology company listed on Nasdaq under the symbol SGHT, has announced its participation in the Morgan Stanley Global Healthcare Conference in New York City. The management will engage in a fireside chat scheduled for September 13, 2022, at 7:20 AM ET. Investors can access a live and archived webcast of the discussion through the 'Investors' section of their website. The company focuses on innovative solutions to improve patient care for eye diseases, including its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease.
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 2:30 PM ET. The event will be held virtually, and interested parties can access a live webcast through the provided link. An archived version will be available on the company's website post-event. Sight Sciences focuses on developing minimally invasive solutions for prevalent eye diseases, including the OMNI Surgical System and TearCare System, aimed at improving patient care.
Sight Sciences has launched SION, a new surgical instrument designed for goniotomy procedures, enhancing patient care in ophthalmic surgeries. SION's bladeless technology allows for smooth tissue removal by grasping diseased tissue without cutting, improving safety and ease of use. Developed with leading surgeons, the instrument is aimed at addressing the growing goniotomy market. CEO Paul Badawi emphasized SION's role in expanding Sight Sciences’ portfolio of minimally invasive solutions, furthering their commitment to innovation in treating prevalent eye diseases.
Sight Sciences (Nasdaq: SGHT) released three-year follow-up data showing the effectiveness of the OMNI Surgical System in treating open-angle glaucoma. The study revealed a mean reduction in intraocular pressure (IOP) of over 20% for all 26 patients, with IOP decreasing from 24.6 mmHg preoperatively to 15.0 mmHg at 36 months. Additionally, the mean number of IOP-lowering medications dropped significantly. Adverse events were minimal and resolved without intervention in most cases. This data underscores the long-term safety and efficacy of the OMNI system as a standalone treatment.